Valneva SE (VALN) Net Income towards Common Stockholders (2021 - 2026)
Valneva SE (VALN) posted Net Income towards Common Stockholders of -$27.7 million for Q1 2026, up 52.41% sequentially from -$58.3 million in Q4 2025, and down 342.51% YoY from $11.4 million in Q1 2025.
Valneva SE (VALN) Net Income towards Common Stockholders (2021 - 2026) Analysis & Trends
Valneva SE has reported Net Income towards Common Stockholders for 6 years, with the latest figure at -$27.7 million in Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 342.51% year-over-year to -$27.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$154.9 million (down 135.6% YoY) and the FY2025 annual result came in at -$134.1 million, down 1029.61% from the prior year.
- Net Income towards Common Stockholders grew to -$27.7 million in Q1 2026 per VALN's latest filing, from -$58.3 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $94.1 million in Q3 2022 and troughed at -$156.3 million in Q2 2022.
- A 5-year average of -$22.5 million and a median of -$24.1 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders surged 516.53% in 2024, then sank 379.79% in 2025.
- Over 5 years, Net Income towards Common Stockholders stood at -$57.5 million in 2022, then jumped by 53.39% to -$26.8 million in 2023, then surged by 54.66% to -$12.1 million in 2024, then tumbled by 379.79% to -$58.3 million in 2025, then soared by 52.41% to -$27.7 million in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$27.7 million, -$58.3 million, and -$56.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Valneva SE | 618.67 Mn | 477.41 Mn | 1.86 Mn | -36.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -36.30 Mn |
| Mar 31, 2026 | -27.74 Mn |
| Dec 31, 2025 | -58.29 Mn |
| Sep 30, 2025 | -56.55 Mn |
| Jun 30, 2025 | -12.30 Mn |
| Mar 31, 2025 | -6.27 Mn |
| Dec 31, 2024 | -12.15 Mn |
| Sep 30, 2024 | -24.12 Mn |
| Jun 30, 2024 | -23.20 Mn |
| Mar 31, 2024 | 74.10 Mn |
| Dec 31, 2023 | -26.80 Mn |
| Sep 30, 2023 | -24.18 Mn |
| Jun 30, 2023 | -20.03 Mn |
| Mar 31, 2023 | -17.79 Mn |
| Dec 31, 2022 | -57.49 Mn |
| Sep 30, 2022 | 94.09 Mn |
| Jun 30, 2022 | -156.31 Mn |
| Mar 31, 2022 | -28.10 Mn |
| Dec 31, 2021 | 193.58 Mn |
| Sep 30, 2021 | -185.83 Mn |